Direct vascular effects of HR780, a novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor

Clinical and Experimental Pharmacology and Physiology

Volumn 30, Issue 12, 2003, Pages 958-962

  Wajima, Teruaki ^a   Makita, Shigeki ^a   Oshima, Kenichi ^a  

^a Aventis Pharma Ltd   (Japan)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A reductase inhibitor; Cell injury; Endothelial cell; HR780; Migration; Proliferation; Smooth muscle cell

Indexed keywords

6 [2 [4 (4 FLUOROPHENYL) 2 ISOPROPYL 6 PHENYL 3 PYRIDYL]VINYL] 3,4,5,6 TETRAHYDRO 4 HYDROXY 2H PYRAN 2 ONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LACTATE DEHYDROGENASE; PLATELET DERIVED GROWTH FACTOR; PRAVASTATIN; PROBUCOL; SIMVASTATIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CELL DAMAGE; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME INHIBITION; IN VITRO STUDY; MALE; NONHUMAN; OXIDATIVE STRESS; PROTEIN TRANSPORT; SMOOTH MUSCLE FIBER;

ANIMALS; AORTA, THORACIC; CELL DIVISION; CELL MOVEMENT; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; FETAL BLOOD; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; L-LACTATE DEHYDROGENASE; MALE; MEVALONIC ACID; MUSCLE, SMOOTH, VASCULAR; PLATELET-DERIVED GROWTH FACTOR; PRAVASTATIN; PROBUCOL; PYRIDINES; RABBITS; SIMVASTATIN; SWINE; XANTHINE; XANTHINE OXIDASE;

EID: 0347416950     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2003.03932.x     Document Type: Article

References (36)

1. MAAS Investigators. Effect of simvastatin on coronary atheroma: The Multicentre Anti-Atheroma Study (MAAS). Lancet 1994; 344: 633-8.
2. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993; 87: 1781-91.
3. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogeniecity. N. Engl. J. Med. 1989; 320: 915-24.
4. Levine GN, Keaney Jr JF, Vita JA. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N. Engl. J. Med. 1995; 332: 512-21.
5. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J. Clin. Invest. 1993; 91: 2546-51.
6. Harrison DG. Endothelial function and oxidant stress. Clin. Cardiol. 1997; 20 (Suppl. 2): II-11-17.
7. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circ. Res. 2000; 87: 840-4.
8. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993; 362: 801-9.
9. Sumi D, Hayashi T, Thakur NK et al. A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects: The relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. Atherosclerosis 2001; 155: 347-57.
10. Rikitake Y, Kawashima S, Takeshita S et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001; 154: 87-96.
11. Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler. Thromb. Vasc. Biol. 2000; 20: 61-9.
12. Hidaka Y, Eda T, Yonemoto M, Kamei T. Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733). Atherosclerosis 1992; 95: 87-94.
13. Bellosta S, Bernini F, Ferri N et al. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 1998; 137 (Suppl.): S101-9.
14. Corsini A, Pazzucconi F, Arnaboldi L et al. Direct effects of statins on the vascular wall. J. Cardiovasc. Pharmacol. 1998; 31: 773-8.
15. Krause R. HR780: A new, highly potent inhibitor of cholesterol synthesis with long biological half-life and selective action on target tissues. Can. J. Cardiol. 1992; 8 (Suppl.): A23-5.
16. Kramer W, Wess G, Enhsen A et al. Bile acid derived HMG-CoA reductase inhibitors. Biochim. Biophys. Acta 1994; 1227: 137-54.
17. Boyden S. The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leucocytes. J. Exp. Med. 1962; 115: 453-66.
18. McCord JM, Fridovich I. Superoxide dismutase. An enzymatic function for erythrocuprein (hemocuprein). J. Biol. Chem. 1969; 244: 6049-55.
19. Brown JM, Terada LS, Grosso MA et al. Hydrogen peroxide mediates reperfusion injury in the isolated rat heart. Mol. Cell Biochem. 1988; 84: 173-5.
20. Fridovich I. Superoxide dismutases. An adaptation to a paramagnetic gas. J. Biol. Chem. 1989; 264: 7761-4.
21. Aust SD, Svingen BA. The role of iron in enzymatic lipid peroxidation. In: Pryor WA (ed.). Free Radicals in Biology. Academic Press, New York. 1982; 1-28.
22. Bridges AB, Scott NA, Belch JJF. Probucol, a superoxide free radical scavenger in vitro. Atherosclerosis 1991; 89: 263-5.
23. McCord JM, Roy RS, Schaffer SW. Free radicals and myocardial ischemia. The role of xanthine oxidase. Adv. Myocardiol. 1985; 5: 183-9.
24. Delbosc S, Morena M, Djouad F, Ledoucen C, Descomps B, Cristol JP. Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are able to reduce superoxide anion production by NADPH oxidase in THP-1-derived monocytes. J. Cardiovasc. Pharmacol. 2002; 40: 611-17.
25. Ross R, The smooth muscle cell. II. Growth of smooth muscle in culture and formation of elastic fibers. J. Cell. Biol. 1971; 50: 172-86.
26. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425-30.
27. Hancock JF, Magee AI, Childs JE, Marshall CJ. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 1989; 57: 1167-77.
28. Schafer WR, Kim R, Sterne R, Thorner J, Kim SH, Rine J. Genetic and pharmacological suppression of oncogenic mutations in RAS genes of yeast and humans. Science 1989; 245: 379-85.
29. Fairbanks KP, Witte LD, Goodman DS. Relationship between mevalonate and mitogenesis in human fibroblasts stimulated with platelet-derived growth factor. J. Biol. Chem. 1984; 259: 1546-51.
30. Axel DI, Riessen R, Runge H, Viebahn R, Karsch KR. Effects of cerivastatin on human arterial smooth muscle cell proliferation and migration in transfilter cocultures. J. Cardiovasc. Pharmacol. 2000; 35: 619-29.
31. Horiuchi M, Cui TX, Li Z, Li JM, Nakagami H, Iwai M. Fluvastatin enhances the inhibitory effects of a selective angiotensin II type I receptor blocker, valsartan, on vascular neointimal formation. Circulation 2003; 107: 106-12.
32. Johnson MD, Woodard A, Okediji EJ, Toms SA, Allen GS. Lovastatin is a potent inhibitor of meningioma cell proliferation: Evidence for inhibition of a mitogen associated protein kinase. J. Neurooncol. 2002; 56: 133-42.
33. Boulton TG, Nye SH, Robbins DJ et al. ERKs: A family of protein-serine/threonin kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 1991; 65: 663-75.
34. Patel R, Nagueh SF, Tsybouleva N et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001; 104: 317-24.
35. Park JK, Muller DN, Mervaala EM et al. Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure-and cholesterol-lowering effects. Kidney Int. 2000; 58: 1420-30.
36. Melchert RB, Liu H, Cranberry MC, Kennedy RH. Lovastatin inhibits phenylephrine-induced ERK activation and growth of cardiac myocytes. Cardiovasc. Toxicol. 2001; 1: 237-52.